New drug combo for rare blood cancer shows early promise, but trial halted
Disease control
Terminated
This early-phase trial tested a combination of two drugs (parsaclisib and chidamide) in 12 people with a rare type of blood cancer called peripheral T-cell lymphoma that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for side eff…
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 16, 2026 23:47 UTC